Table 2.

Medication use for patients with vitiligo following diagnosis: 12-month follow-up (N = 19,335)

	Oral CS (N = 4063)	HTCS (N = 3908)	MTCS (N = 2029)	LTCS (N = 407)	TCI (N = 2725)	Immunosuppressants (N = 430)
Number of medication claims	1.9 (2.0)	1.6 (1.3)	1.4 (1.0)	1.3 (0.9)	1.7 (1.4)	4.4 (3.7)
Time to first medication claim (days)	153.3 (108.3)	72.8 (100.3)	91.2 (108.8)	93.7 (114.0)	56.8 (89.2)	111.6 (107.7)
Total days supplied	26.3 (62.0)	37.9 (36.6)	33.8 (29.4)	30.0 (26.8)	44.8 (39.9)	185.8 (149.6)
Number of treated days	23.2 (48.8)	35.8 (32.4)	32.4 (26.7)	28.9 (25.2)	42.9 (36.0)	152.2 (110.9)

Data are mean (SD)

N = 9648 (49.9%) patients did not receive any treatment during the 12-month follow-up

CS corticosteroid, HTCS high-potency CS, LTCS low-potency CS, MTCS medium-potency CS, SD standard deviation, TCI topical calcineurin inhibitors